Alcon制药公司在美国上市了新非甾体抗炎(NSAI)前体药物nepafenac(暂译名:萘帕芬胺,Nevanac)0．1％眼用混悬液,用于治疗白内障手术后相关疼痛和炎症。公司称Nevanac将成为首个FDA批准的眼用NSAI前体药物(其老的NSAID名为氨芬酸),也是唯一治疗白内障手术后相关疼痛和炎症的前体药物。其渗透角膜的能力很强,能到达所有的炎症目标位点,包括黄斑。渗透角膜的作用很重要,因为大多数医生使用NSAIDs都是用来预防或治疗眼后囊样斑点水肿。Nevanac在抑制眼炎症相关的前列腺 Alcon Pharmaceuticals Inc. has listed a 0.1% ophthalmic suspension of nepafenac, a novel non-steroidal anti-inflammatory (NSAI) prodrug, in the United States for the treatment of post-cataract-related pain and Inflammation. The company said Nevanac will be the first FDA-approved ophthalmic NSAI prodrug (its oldest NSAID is amphetamine) and the only prodrug to treat pain and inflammation associated with cataract surgery. Its ability to penetrate the cornea is very strong and reaches all of the inflammatory target sites, including the macula. Corneal penetration is important because most physicians use NSAIDs to prevent or treat posterior capsular edema. Nevanac suppresses ocular inflammation-associated prostate